KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab regimens for patients with PD-L1 positive, platinum-resistant ovarian cancers. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results